# FDA 483 - Stephane Leung Wai Sang, MD - February 24, 2026

Source: https://www.keypedia.com/records/483/stephane-leung-wai-sang-md/6239c5ed-4069-4be9-a1f8-fa34e8692dcc

> FDA 483 for Stephane Leung Wai Sang, MD on February 24, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Stephane Leung Wai Sang, MD
- Inspection Date: 2026-02-24
- Product Type: drugs
- Office Name: Detroit District Office
- Summary: An FDA inspection of Stephane Leung Wai Sang, MD, a clinical investigator in Grand Rapids, MI, revealed a significant failure to adhere to the investigational plan. The primary issue identified was the inadequate and untimely reporting and documentation of adverse events, including serious adverse event assessments. This indicates a serious lapse in clinical trial conduct and oversight of patient safety.

## Related Officers

- [investigator](https://www.keypedia.com/people/chelsea-w-lamm/d7a8dd67-dc26-4c8a-8e3c-aebc267cb775)

Company: https://www.keypedia.com/companies/stephane-leung-wai-sang-md/e82790fb-1295-4600-9697-450fd05a87ea

Office: https://www.keypedia.com/offices/detroit-district-office/b09a1815-a000-40c0-bb44-5432ce87ed03